Economic burden of multiple sclerosis: What can we learn from cost-of-illness studies?

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 6, Issue 2, 2006, Pages 145-154

  Orlewska, Ewa ^a  

^a Centre for Pharmacoeconomics   (Poland)

Author keywords

Burden of disease; Cost of illness study; Multiple sclerosis

Indexed keywords

GLATIRAMER; INTERFERON;

ARTICLE; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DATA ANALYSIS; DISEASE SEVERITY; ECONOMIC EVALUATION; EXPANDED DISABILITY STATUS SCALE; FINANCIAL MANAGEMENT; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH ECONOMICS; HEALTH SERVICE; HUMAN; MEDICAL LITERATURE; MEDICAL RESEARCH; METHODOLOGY; MULTIPLE SCLEROSIS; RESOURCE ALLOCATION;

EID: 33646115814     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/14737167.6.2.145     Document Type: Article

References (56)

1. Weinshenker BG, Bass B, Rice GP et al. The natural history of multiple sclerosis - a geographically based study. Brain 112, 133-146 (1989).
2. Poser S, Kurtzke JF, Poser W et al. Survival in multiple sclerosis. J. Clin. Epidemiol. 42, 159-168 (1989).
3. Bronnum-Hansen H, Koch-Henriksen N, Hyllested K. Survival of patients with multiple sclerosis in Denmark: a nationwide, long-term epidemiologic survey. Neurology 44, 1901-1907 (1994).
4. Hauser SL. Multiple sclerosis and other demyelinating diseases. In: harrison's Principles of Internal Medicine. 13th Ed. Isselbacher KJ, Braunwald E, Wilson JD et al. (Eds). McGraw-Hill, Inc. NY, USA, 2281-2294 (1994).
5. Reumont MJ, Deluca SA. Neuroimaging evaluation in multiple sclerosis. Am. Farm. Physician 48 (2), 273-276 (1993).
6. Hibbard PL. The use and misuse of statistics for epidemiological studies of multiple sclerosis. Ann. Neurol. 36(S2), S218-S130 (1994).
7. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinschenker BG. Medical progress: multiple sclerosis. N. Eng. J. Med. 343, 938-952 (2000).
8. Rao SM, Leo GJ, Ellington L et al. Cognitive dysfunction in multiple sclerosis. II. Impact on unemployment and social functioning. Neurology 4l, 692-696 (1991).
9. Bauer HJ, Firnhaber W, Winkler W. Prognostic criteria in multiple sclerosis. Ann. NY Acad. Sci. 122 (1), 542-551 (1965).
10. LaRoca N, Kalb R, Kendall P et al. The role of disease and demographic factors in the employment of patients with multiple sclerosis. Arch. Neurol. 39, 256 (1982).
11. IFNβ Multiple Sclerosis Study Group. Interferon β-1b is effective in relapsing-remitting multiple sclerosis. Neurology 43, 655-661 (1993).
12. Jacobs LD, Cookfair DL, Rudick RA et al. Intramuscular interferon β-la for disease progression in relapsing multiple sclerosis. Ann. Neurol, 39, 285-294 (1996).
13. Rudick RA, Goodkin DE, Jacobs LD et al. Impact of interferon β-1a on neurologic disability in relapsing multiple sclerosis. Neurology 49, 358-363 (1997).
14. The IFNβ Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon β-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 45, 1277-1285 (1995).
15. Johnson KP, Brooks BR, Cohen JA et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a Phase III multicenter, double-blind, placebo controlled trial. Neurology 45, 1268-1276 (1995).
16. Larson LN. Cost determination and analysis. In: Principles of Pharmacoeconomics. Bootman JL, Townsend RJ, McGahan WF (Eds). Harvey Whitney Books Co, OH, USA, 44-59 (1996).
17. Rice DP. Cost-of-illness studies: fact or fiction? Lancet 344, 1519-1520 (1994).
18. Hodgson TA. Cost of illness in cost-effectiveness analysis: a review of the methodology. Pharmacoeconomics 6(6), 536-552 (1994)
19. Shiell A, Gerard K, Donaldson C. Cost of illness studies: an aid to decision making? Health Policy 8, 317-323 (1987).
20. Drummond M. Cost of illness studies: a major headache? Pharmacoeconomics 2(l), 1-4 (1992).
21. Holmes BA, Madgwick T, Bates D. The cost of MS. Br. J. Med. Econ. 8, 181-193 (1995).
22. Blumhardt LD, Wood C. The economics of MS: a cost of illness study. Br. J. Med. Econ. 10, 99-118 (1996).
23. Midgard R, Rise T, Nyland H. Impairment, disability and handicap in multiple sclerosis. A cross-sectional observational study in More and Romsdal County, Norway. J. Neurol. 337-344 (1996).
24. Asche CV, Ho E, Chan B et al. Economic consequences of MS for Canadians. Acta Neurol. Scand. 95, 268-274 (1997).
25. Henriksson F, Jonsson B. The economic cost of multiple sclerosis in Sweden in 1994. Pharmacoeconomics 13, 597-606 (1998).
26. Bourdette DN, Prochazka AV, Mitchell W, Licari P, Burks J. Health care costs of veterans with multiple sclerosis: implications for the rehabilitation of MS. VA Multiple Sclerosis Rehabilitation Study Group. Arh. Phys. Med. Rehabil. 74, 26-31 (1993).
27. Stolp-Smith KA, Atkinson EJ, Campion ME, OBrien PC, Rodriguez M. Health care utilization in multiple sclerosis: a population-based study in Olmstead County, MN. Neurology 50, l594-l600 (1998).
28. The Canadian Burden of Illness Study Group. Burden of illness of multiple sclerosis: part I: cost of illness. Can. J. Neurol. Sci. 25, 23-30 (1998).
29. Grima DT, Torrance GW, Francis G, Rice G, Rosner AJ, Lafortune L. Cost and health related quality of life consequences of multiple sclerosis. Mult. Scler. 6, 91-98 (2000).
30. Carton H, Loos R, Pacolet J, Versieck K, Vlietinck R. Utilization and cost of professional care and assistance according to disability of patients with multiple sclerosis in Flanders (Belgium). J. Neurol. Neurosurg. Psychiatry 64, 444-450 (1998).
31. Carton H, Loos R, Pacolet J, Versieck K, Vlietinck R. A quantitative study of unpaid caregiving in multiple sclerosis. Mult. Scler. 6, 274-279 (2000).
32. Murphy N, Confavreux C, Haas J, Konig N, Roullet E, Sailer M et al. Economic evaluation of multiple sclerosis in the U.K., Germany and France. Pharmacoeconamics 13, 607-622 (1998).
33. Henriksson F, Fredrikson S, Masterman T, Jonsson B. Costs, quality of life and disease severity in multiple sclerosis: a cross-sectional study in Sweden. Eur J. Neurol. 8, 27-35 (2001).
34. Kobelt G, Lindgren P, Smala A, Jonsson B. German Cost of MS Study Group. Costs and quality of life in multiple sclerosis: an observational study in Germany. HEPAC 2, 60-68 (2001).
35. Amato MP, Battaglia MA, Caputo D et al. The costs of multiple sclerosis: a cross-sectional, multicenter cost-of-illness study in Italy. J. Neurol. 249, 152-163 (2002).
36. Orlewska E, Mierzejewski P, Zaborski J et al. A prospective study of the financial costs of multiple sclerosis at different stages of the disease. Eur. J. Neurol. 12, 31-39 (2005).
37. Grudzinski AN, Hakim Z, Cox ER, Bootman JL. The economics of multiple sclerosis. Distribution of costs and relationship to disease severity. Pharmacoeconomics 15 (3), 229-240 (1999).
38. Kobelt G. Economic evidence in multiple sclerosis: a review. Eur. J. Health Econ. (Suppl. 1), S54-S62 (2004).
39. Parwardhan MB, Matchar DB, Samsa GP, McCrory DC, Williams RG, Li TT. Cost of multiple sclerosis by level of disability: a review of literature. Mult. Scler. 11, 232-239 (2005).
40. Kobelt G, Puglatti M. Cost of multiple sclerosis in Europe. Eur. J. Neurol. (Suppl. 1), 63-67 (2005)
41. Drummond MF, O'Brien B, Stoddart LG et al. Methods for Economic Evaluation of Health Care Programmes (2nd Ed.). Oxford, Oxford University Press, UK, 209-212 (1997).
42. Koopmanschap MA, Rutten FFH, van Ieveld BM et al. The friction-cost method for estimating the indirect costs of disease. J. Health Econ. 14, 171-189 (1995).
43. Luce BR, Manning WG, Siegel JE, Lipscomb J. Estimating costs in cost - effectiveness analysis. In: Costs - Effectiveness in Health and Medicine Gold M, Siegel J et al. (Eds). Oxford University Press, NY, USA, 176-213 (1996).
44. Brouwer WBF, Koopmanschap MA, Rutten FFH. Productivity costs in cost - effectiveness analysis: numerator or denominator: a further discussion. Health Econ. 6, 511-514 (1997)
45. Liljas B. How to calculate indirect costs in economic evaluations. Pbarmacoeconomics 13, 1-7 (1998).
46. Sculpher M. The role and estimation of productivity costs in economic evaluation. In: Economic Evaluation in Health Care: Merging Theory with Practice. Drummond MF, Mcguire A (Eds). Oxford, Oxford University Press, UK (2001).
47. Guidelines for the pharmaceutical industry on preparation of submission to the pharmaceutical Benefits Advisory Committee. Canberra: Commonwealth Department of Human Services (1995).
48. Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Guidelines for economic evaluation of pharmaceuticals. 2nd Ed. Ottawa, ON, Canada (1997).
49. Riteco JA, De Heij LJM, van Luijn JCF et al. Dutch guidelines: pharmacoeconomic research guidelines Amstelveen: CvZ (1999)
50. Siegel JE, Torrance GW, Russel LB et al. Guidelines for pharmacoeconomic studies. pharmacoeconomics 11 (2), 159-168 (1997)
51. Gold MR, Siegel JE, Russell LB et al. (Eds). Cost - effectiveness in health and medicine. Oxford University Press, NY, USA, 181-183 (1996)
52. Koopmanschap M, Burdorf A, Jacob K, Meerding WJ, Brouwer W, Severens H. Measuring productivity changes in economic evaluation. Setting the research agenda. Pharmacoeconomics 23(1), 47-54 (2005).
53. Smith K, Wright K. Informal care and economic appraisal: a discussion of possible methodological approaches. Health Econ. 3, 137-148 (1994).
54. Posnett J, Jan S. Indirect cost in economic evaluation: the opportunity cost of unpaid inputs. Health Econ. 5, 13-23 (1996).
55. 55 van den Berg B, Brouwer B. Koopmanschap MA. Economic evaluation of informal care. An overview of methods and applications. Eur. J. Health Econ. 5(1), 36-45 (2004).
56. Torrance G. Measurment of health state utilities for economic appraisal. A review. J. Health Econ. 5, 1-30 (1998).